Overview
- CSL reported a net loss of US$2.6 billion for fiscal 2025/26 with total revenue down 1% to US$15.8 billion after US$7.1 billion in pre-tax writedowns mainly tied to CSL Vifor.
- The 2022 acquisition of Vifor, which cost about US$11.7 billion, has underperformed because of competition from generic drugs and regulatory changes that reduced its sales outlook.
- Interim chief executive Gordon Naylor described FY2026 as a 'reset year' and said management has started an urgent transformation while the company continues to seek a permanent CEO.
- Commercial headwinds that hit revenues included weaker albumin demand in China and lower influenza vaccination rates in the United States.
- Shares jumped more than 16% after results beat consensus but analysts warn Vifor will weigh on group growth and investors will likely need patience for a sustained recovery.